Trial Profile
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Non Valvular Atrial Fibrillation in Patients Aged 80 Years and Over, Living at Home or in Nursing Home. A Prospective Cohort Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Acenocoumarol; Fluindione; Warfarin
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRESAGE-ACO
- 28 Mar 2022 Status changed from recruiting to completed.
- 17 Jan 2020 Planned End Date changed from 1 Apr 2021 to 1 Nov 2021.
- 17 Jan 2020 Planned primary completion date changed from 1 Apr 2019 to 1 Nov 2021.